查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951251

氣喘治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、給藥方式、通路、地區及競爭格局分類，2021-2031年）

Asthma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Mode of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球氣喘治療市場預計將從 2025 年的 289.2 億美元成長到 2031 年的 379.2 億美元，複合年成長率達到 4.62%。

此領域涵蓋多種藥物治療方法和給藥系統，包括吸入性皮質類固醇、支氣管擴張劑和生物製藥，旨在抑制慢性發炎和緩解急性氣道狹窄。主要成長促進因素包括全球呼吸系統疾病發生率的上升，而這又受到快速都市化、空氣污染加劇以及環境過敏原暴露增加的影響。日益加重的疾病負擔凸顯了製定有效長期照護策略的必要性，並持續推動對治療方案的需求。根據世界氣喘日的數據，到2024年，氣喘將影響超過2.6億人，導致全球約45萬人死亡，凸顯了普及醫療保健的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 289.2億美元
市場規模：2031年 379.2億美元
複合年成長率：2026-2031年 4.62%
成長最快的細分市場 網路藥房
最大的市場 北美洲

儘管市場呈現積極的成長趨勢，但現代治療方法的成本和可及性仍然是市場面臨的重大障礙。生物製藥和先進吸入器的高昂價格限制了病患的用藥，尤其是在醫療資源匱乏的中低收入地區。此外，患者對處方治療方案的依從性差也是一大障礙，這不僅降低了治療效果，也限制了製藥公司的潛在收入。這些經濟和行為的挑戰持續阻礙全球氣喘治療產業的更廣泛發展和應用。

市場促進因素

氣喘和慢性呼吸系統疾病在全球範圍內的盛行率不斷上升，這主要受快速都市化和環境污染物暴露增加的影響，也是市場成長的關鍵促進因素。隨著醫療系統努力應對日益嚴重的呼吸道發炎負擔，不斷成長的患者群體對有效的維持治療的需求也日益迫切。現有維持治療藥物的強勁表現反映了這一趨勢的商業性意義，這些藥物對於日常症狀管理至關重要。例如，葛蘭素史克（GSK）在2025年2月報告稱，其呼吸系統維持治療藥物Trelegy在2024年的銷售額成長了27%，這凸顯了在全球呼吸系統健康狀況日益惡化的背景下，持續的疾病管理至關重要。

同時，針對重度、難治性氣喘患者特定需求的生物目標和單株抗體的湧現，正在重新定義市場價值。這些精準藥物旨在抑制嗜酸性粒細胞和IgE等特定發炎通路，與標準皮質類固醇相比，它們具有更優的治療效果，從而能夠實現高價定價並顯著提高收入。這些新一代藥物的快速普及顯而易見。 2025年2月，Astra Zeneca宣布其新型生物製藥TedSpir在2024年全年銷售額達12.2億美元，標誌著精準醫療正朝著個人化方向發展。此外，該領域的規模也從其旗艦產品中可見一斑。 2025年2月，再生元公司報告稱，其重磅生物製藥Dupixent在2024年的全球淨銷售額成長了22%，達到141.5億美元，證實了精準藥物將對整個市場產生重大的經濟影響。

市場挑戰

先進藥物治療方法和給藥機制的高成本是全球氣喘治療市場發展的一大障礙。儘管臨床上對生物製藥和先進吸入器的需求日益成長，但這些藥物的高昂成本限制了它們的使用，尤其是在醫療報銷有限的地區。面對高額的自付費用，患者更有可能漏服藥物或徹底放棄治療。這種經濟阻力會降低處方箋續藥率，並縮小藥物研發者可觸及的有效市場，從而阻礙市場成長。

這種經濟壓力導致氣喘的高發生率與實際產生收入之間出現脫節。根據美國氣喘和過敏基金會估計，到2025年，美國氣喘的年度經濟成本將達到約820億美元，這將造成巨大的負擔，使得持續治療的資金籌措變得困難。因此，支付方經常實施嚴格的處方藥限制以控制成本，進一步限制了患者獲得有效治療的機會。除非經濟可近性與日益成長的疾病負擔之間的差距得以彌合，否則市場將難以充分發揮其商業性潛力。

市場趨勢

隨著製造商調整其呼吸系統藥物產品組合以滿足嚴格的環境標準，開發環保、低全球暖化潛勢 (GWP) 的吸入器正在樹立新的行業標準。這一趨勢包括使用 HFA-152a 等先進推進劑重新設計壓力定量吸入器 (pMDI)，從而在不影響臨床療效的前提下，顯著降低常規治療相關的碳排放。綠色製造和配方改良舉措的巨額投資也印證了這一行業轉型。例如，凱西製藥 (Chiesi Farmaceutici) 在其 2025 年 6 月發布的《2024 年永續發展報告》中重點介紹了一項超過 3.5 億歐元的策略性投資，用於替換現有推進劑，旨在將其產品的碳足跡減少高達 90%，同時確保長期符合監管要求。

同時，具成本效益的生物相似藥和複雜學名藥的推出，正在改變商業格局，挑戰現有生物製藥在重度氣喘治療領域的市場主導地位。隨著關鍵單株抗體的專利保護到期，可互換生物相似藥的核准為支付方和醫療網路提供了成本更低的治療選擇，擴大了患者獲得高品質治療的機會，而這些治療此前曾因預算限制而受限。這種邁向可負擔精準醫療的趨勢也在監理層面加速推進。 2025年3月，Celltrion公司發布新聞稿，宣布其Omalizumab單抗生物相似藥獲得美國FDA核准，標題為「FDA核准Omliclo為首個與Zolia可互換的生物相似藥」。這項重要里程碑將為原廠藥帶來價格競爭，並擴大生物製劑級氣喘治療的市場。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球氣喘治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（短效BETA2受體激動劑（SABA）、長效BETA2受體激動劑（LABA）、吸入性皮質類固醇（ICS）、白三烯調節劑、免疫調節劑、複方藥物及其他）
    • 依給藥途徑（吸入器、霧化器、口服藥物）
    • 通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球氣喘治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline, Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim Gmbh
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Roche Holding AG
  • Regeneron Pharmaceutical Inc.
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15533

The Global Asthma Treatment Market is projected to expand from USD 28.92 Billion in 2025 to USD 37.92 Billion by 2031, achieving a CAGR of 4.62%. This sector encompasses a wide array of pharmacological treatments and delivery systems, such as inhaled corticosteroids, bronchodilators, and biologic agents, all aimed at controlling chronic inflammation and relieving acute airway constriction. The main forces driving this growth include the increasing global incidence of respiratory disorders, which are fueled by rapid urbanization, worsening air pollution, and higher exposure to environmental allergens. Such a rising disease burden creates a critical need for effective long-term care strategies, sustaining the demand for therapeutic solutions. Data from the Global Initiative for Asthma indicates that in 2024, the condition impacted over 260 million people and resulted in roughly 450,000 deaths worldwide, emphasizing the urgent demand for accessible medical care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 28.92 Billion
Market Size 2031USD 37.92 Billion
CAGR 2026-20314.62%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Despite these positive growth trends, the market encounters significant obstacles related to the cost and accessibility of modern therapies. The high price points of biologic medications and advanced inhaler devices limit patient access, particularly in low-to-middle-income areas where healthcare reimbursement structures are often inadequate. Additionally, poor patient adherence to prescribed treatment plans acts as a major barrier, lowering therapeutic effectiveness and constraining potential revenue for pharmaceutical companies. These combined economic and behavioral challenges continue to hinder the broader development and reach of the global asthma treatment industry.

Market Driver

The rising global prevalence of asthma and chronic respiratory conditions serves as the primary engine for market growth, underpinned by rapid urbanization and increasing exposure to environmental pollutants. This escalation in patient numbers generates a continuous, essential demand for effective maintenance treatments as healthcare systems strive to cope with the expanding burden of airway inflammation. The commercial significance of this trend is reflected in the strong performance of established maintenance therapies, which are crucial for daily symptom control. For example, GSK reported in February 2025 that sales of its respiratory maintenance product, Trelegy, grew by 27% in 2024, highlighting the vital requirement for consistent disease management amidst deteriorating global respiratory health.

Concurrently, the uptake of targeted biologic therapies and monoclonal antibodies is redefining market value by meeting the specific needs of severe, uncontrolled asthma cases. These precision medicines, designed to block specific inflammatory pathways like those involving eosinophils or IgE, provide better outcomes than standard corticosteroids, allowing for premium pricing and significant revenue expansion. The swift adoption of these next-generation drugs is evident; AstraZeneca noted in February 2025 that full-year 2024 sales for its novel biologic, Tezspire, hit $1.22 billion, signaling a transition toward personalized treatment. Furthermore, the magnitude of this segment is illustrated by leading products; Regeneron reported in February 2025 that global net sales for the blockbuster biologic Dupixent increased by 22% to $14.15 billion in 2024, confirming the major financial impact of precision therapeutics on the total market.

Market Challenge

The elevated costs associated with advanced pharmacological treatments and delivery mechanisms pose a major hurdle to the Global Asthma Treatment Market's progression. While the clinical need for biologics and modern inhalers is increasing, the high price tags of these premium options restrict their usage, especially in areas with limited healthcare reimbursement. When patients are confronted with substantial out-of-pocket costs, they are statistically more prone to skipping doses or abandoning treatment altogether. This economic friction impedes market growth by lowering prescription refill rates and effectively narrowing the addressable market for pharmaceutical developers.

This financial pressure creates a disconnect between the high disease prevalence and actual revenue generation. According to the Asthma and Allergy Foundation of America, the estimated annual economic cost of asthma in the United States reached approximately $82 billion in 2025, representing a massive burden that makes funding consistent care difficult. As a result, payers frequently implement rigorous formulary restrictions to control costs, which further limits patient access to effective therapies. Until the gap between economic accessibility and the increasing disease burden is bridged, the market will face difficulties in achieving its full commercial capabilities.

Market Trends

The creation of eco-friendly, low-global warming potential (GWP) inhalers is setting a new industry benchmark as manufacturers adjust their respiratory portfolios to meet strict environmental standards. This trend entails redesigning pressurized metered-dose inhalers (pMDIs) to use advanced propellants such as HFA-152a, which drastically lower the carbon emissions associated with daily treatment without reducing clinical effectiveness. This industry shift is demonstrated by significant investments in green manufacturing and reformulation initiatives. For instance, in its '2024 Sustainability Report' released in June 2025, Chiesi Farmaceutici highlighted a strategic investment exceeding €350 million to replace existing propellants, aiming to cut the product's carbon footprint by up to 90% while ensuring long-term regulatory adherence.

At the same time, the introduction of cost-efficient biosimilars and complex generics is transforming the commercial environment by challenging the market dominance of established biologic therapies for severe asthma. As patent protections for major monoclonal antibodies expire, the authorization of interchangeable biosimilars offers payers and healthcare networks lower-cost options, thereby broadening patient access to premium treatments that were once limited by budgetary constraints. This movement toward affordable precision medicine is gathering regulatory speed. In March 2025, Celltrion announced in a press release titled 'FDA Approves Omlyclo as First Interchangeable Biosimilar to Xolair' that it had received U.S. clearance for its omalizumab biosimilar, a key event that brings price competition to the reference product and expands the market for biologic-quality asthma care.

Key Market Players

  • GlaxoSmithKline, Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim Gmbh
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Roche Holding AG
  • Regeneron Pharmaceutical Inc.
  • Pfizer Inc.

Report Scope

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Class

  • Short-Acting Beta-Agonists (SABA)
  • Long-Acting Beta-Agonists (LABA)
  • Inhaled Corticosteroids (ICS)
  • Leukotriene Modifiers
  • Immunomodulators
  • Combination Drugs
  • Others

Asthma Treatment Market, By Mode of Administration

  • Inhalers
  • Nebulizers
  • Oral Medications

Asthma Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Asthma Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Treatment Market.

Available Customizations:

Global Asthma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others)
    • 5.2.2. By Mode of Administration (Inhalers, Nebulizers, Oral Medications)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Asthma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Mode of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Asthma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Mode of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Asthma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Mode of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Asthma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Mode of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Mode of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Asthma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Mode of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Asthma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Mode of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Asthma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Mode of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Asthma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Mode of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Asthma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Mode of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Asthma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Mode of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Asthma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Mode of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Asthma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Mode of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Asthma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Mode of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Asthma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Mode of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Asthma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Mode of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Asthma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Mode of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Asthma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Mode of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Asthma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Mode of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Asthma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Mode of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Asthma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Mode of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Asthma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Mode of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Asthma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Mode of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Asthma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Mode of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Asthma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline, Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca Plc
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. Boehringer Ingelheim Gmbh
  • 15.5. Merck & Co. Inc.
  • 15.6. Novartis AG
  • 15.7. Sanofi SA
  • 15.8. Roche Holding AG
  • 15.9. Regeneron Pharmaceutical Inc.
  • 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer